These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 36181401)
1. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. Simadibrata DM; Syam AF; Lee YY J Gastroenterol Hepatol; 2022 Dec; 37(12):2217-2228. PubMed ID: 36181401 [TBL] [Abstract][Full Text] [Related]
2. Treatment of Kanu JE; Soldera J World J Gastroenterol; 2024 Mar; 30(9):1213-1223. PubMed ID: 38577188 [TBL] [Abstract][Full Text] [Related]
3. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease. Simadibrata DM; Lesmana E; Fass R J Gastroenterol Hepatol; 2024 May; 39(5):796-805. PubMed ID: 38263507 [TBL] [Abstract][Full Text] [Related]
4. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice. Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444 [TBL] [Abstract][Full Text] [Related]
5. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636 [TBL] [Abstract][Full Text] [Related]
6. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials. Zhang M; Pang M; Zhang M Clinics (Sao Paulo); 2022; 77():100058. PubMed ID: 35810638 [TBL] [Abstract][Full Text] [Related]
8. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Jung YS; Kim EH; Park CH Aliment Pharmacol Ther; 2017 Jul; 46(2):106-114. PubMed ID: 28497487 [TBL] [Abstract][Full Text] [Related]
9. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials. Simadibrata DM; Lesmana E; Fass R J Gastroenterol Hepatol; 2024 Jun; 39(6):988-999. PubMed ID: 38353152 [TBL] [Abstract][Full Text] [Related]
10. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors. Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A Digestion; 2017; 96(1):52-59. PubMed ID: 28662503 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials. Yang C; Li S; Huang T; Lin H; Jiang Z; He Y; Yuan J; An H J Clin Pharm Ther; 2022 Jul; 47(7):897-904. PubMed ID: 35247003 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Lyu QJ; Pu QH; Zhong XF; Zhang J Biomed Res Int; 2019; 2019():9781212. PubMed ID: 31211144 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials. Sun Y; Yue L; Hu W Eur J Clin Pharmacol; 2023 Feb; 79(2):279-288. PubMed ID: 36527456 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of potassium-competitive acid inhibitors in the treatment of gastroesophageal reflux: a systematic review and meta-analysis. Zhou X; Duan H; Li Q; Wang Q; Sun X Scand J Gastroenterol; 2024 Jul; 59(7):788-797. PubMed ID: 38741565 [TBL] [Abstract][Full Text] [Related]
17. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? Dong SQ; Singh TP; Wei X; Yao H; Wang HL Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28884937 [TBL] [Abstract][Full Text] [Related]